Drugs

Article	Citations
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments	502
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression	464
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	375
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments	236
Aprocitentan: First Approval	210
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled,	186
Senaparib: First Approval	178
Targeting DNA Damage Response Deficiency in Thoracic Cancers	166
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using	142
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	141
Teclistamab: First Approval	139
Epcoritamab: First Approval	137
Eftrenonacog Alfa: A Review in Haemophilia B	128
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”	122
New Therapies on the Horizon for Primary Biliary Cholangitis	121
Spesolimab for the Treatment of Generalized Pustular Psoriasis	118
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences	115
Vorasidenib: First Approval	107
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial	104
Ivarmacitinib Sulfate: First Approval	103
Cosibelimab: First Approval	102
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?	101
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine	100
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer	99
Drugs in Development to Manage Acute Pain	95

Acoltremon: First Approval	95
Androgenetic Alopecia: Therapy Update	95
Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms	88
Lenacapavir: First Approval	87
Atogepant: First Approval	87
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies	84
Danicopan: First Approval	82
Repotrectinib: First Approval	82
Olipudase Alfa: First Approval	81
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?	81
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure	81
Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis	81
Mazdutide: First Approval	78
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema	78
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection	77
Cancer Pain Treatment Strategies in Patients with Cancer	75
Olverembatinib: First Approval	74
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification	69
Mosunetuzumab: First Approval	68
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	67
Managing Burning Mouth Syndrome: Current and Future Directions	64
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids	64
Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections	64
Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?	63
Correction to: Tapinarof Cream 1%: First Approval	63
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough	61
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	60
Correction to: Prevention and Treatment of Monkeypox	60
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis	59
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology	59
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options	58
Pozelimab: First Approval	58
The Place of Cannabinoids in the Treatment of Gynecological Pain	57
Sunvozertinib: First Approval	57
Tovorafenib: First Approval	57
Ifupinostat: First Approval	57
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A	56
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned	56
Dorzagliatin: First Approval	55
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer	54
Correction to: Concizumab: First Approval	54
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study	53
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond	53
Catumaxomab: First Approval	52
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?	52
Givinostat: First Approval	50
Ozoralizumab: First Approval	50
Aumolertinib: A Review in Non-Small Cell Lung Cancer	50
Tirzepatide: A Review in Type 2 Diabetes	49
Birch Bark Extract: A Review in Epidermolysis Bullosa	49

The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab	48
Correction to: Remdesivir: A Review in COVID-19	48
Correction: From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology	47
Asciminib: First Approval	47
Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy	46
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials	45
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses	43
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence	43
Correction to: Efmoroctocog Alfa: A Review in Haemophilia A	42
Current and Emerging Treatments for Acid Sphingomyelinase Deficiency	42
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’	42
Gepirone Extended-Release: First Approval	42
Ensitrelvir Fumaric Acid: First Approval	41
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy	41
Atrasentan: First Approval	41
Fezolinetant: First Approval	41
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults	41
Futibatinib: First Approval	39
Tisotumab Vedotin: First Approval	39
Avacincaptad Pegol: First Approval	38
Correction: Teprotumumab: A Review in Thyroid Eye Disease	38
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study	38
Eye Involvement and Management in Inherited Epidermolysis Bullosa	37
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets	37
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets	37
Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes	37
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials	36
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations	36
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1	35
Imetelstat: First Approval	35
Tebentafusp: First Approval	35
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis	35
Correction: Iptacopan: First Approval	34
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases	34
Zastaprazan: First Approval	34
Managing Pain in Fibromyalgia: Current and Future Options	34
Lotilaner Ophthalmic Solution 0.25%: First Approval	33
Beremagene Geperpavec: First Approval	33
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?	33
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease	33
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease	32
Gastrointestinal Dysfunction in Parkinson’s Disease	32
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry	31
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	31
Correction to: Pharmacological Approaches to Managing Violence and Aggression in Prison Populations: Clinical and Ethical Issues	31
Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid	31
Acknowledgement to Referees	31
Mavorixafor: First Approval	30
Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”	30
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials	30
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes	30
Retifanlimab: First Approval	30
Revumenib: First Approval	30
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management	29
Sepiapterin: First Approval	29
Diagnosis and Treatment of AL Amyloidosis	29
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews	29
Nogapendekin alfa Inbakicept: First Approval	28
Correction: Zastaprazan: First Approval	28
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	28
Correction to: Sparsentan: First Approval	28
Crinecerfont: First Approval	28
Correction to: Abrocitinib: First Approval	28
Methadone for Cancer Pain Management in Children: A Review of Literature	27
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study	27
Onradivir: First Approval	27
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy	27
Keverprazan Hydrochloride: First Approval	27
Antibacterials with Novel Chemical Scaffolds in Clinical Development	27
Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy	26
Correction to: Spesolimab: First Approval	26
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer	26
Remdesivir: A Review in COVID-19	26
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval	26
Ravulizumab: A Review in Generalised Myasthenia Gravis	25
Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis	25
Zolbetuximab: First Approval	25
Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”	25
Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial	25
Daridorexant: First Approval	25

Novel Drug Therapeutics in Celiac Disease: A Pipeline Review	25
Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clos	24
Abrocitinib: First Approval	24
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation	24
Marstacimab: First Approval	24
Regdanvimab: First Approval	24
Nadofaragene Firadenovec: First Approval	24
Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases	24
Spesolimab: First Approval	24
Treatment of Osteoporosis and Osteoarthritis in the Oldest Old	24
Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy	24
Lecanemab: First Approval	23
Comment on: “Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing”	23
Amubarvimab/Romlusevimab: First Approval	23
Elranatamab: First Approval	23
Molnupiravir: First Approval	23
Correction to: Mavacamten: First Approval	23
Gefapixant: First Approval	23
Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management	23
Correction to: Rozanolixizumab: First Approval	23
Pucotenlimab: First Approval	22
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions	22
Chiglitazar: First Approval	22
Ritlecitinib: First Approval	22
Tofersen: First Approval	22
Tixagevimab + Cilgavimab: First Approval	22
Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis	22
Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study	21
Comment on “Trientine Tetrahydrochloride, From Bench to Bedside: A Narrative Review”	21
Acknowledgement to Referees	21
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis	20
Correction to: Ozanimod: A Review in Ulcerative Colitis	20
Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?’	20
Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments	20
Trastuzumab Rezetecan: First Approval	20
Valoctocogene Roxaparvovec: First Approval	20
Eplontersen: First Approval	20
Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline	20
Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer	20
Differentiating IL-23 Inhibitors in Crohn’s Disease	20
Elafibranor: First Approval	20
Talquetamab: First Approval	19
Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action	19
Gepotidacin: First Approval	19
New Developments in Glucagon Treatment for Hypoglycemia	19
Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition	19
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders	19
PI3K Inhibitors as Potential Therapeutic Agents for the Treatment of COPD with Associated Atherosclerosis	18
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder	18
20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults	18
PCSK9 Inhibitors: A Potential Priority Choice for Lipid Management in Patients with Diabetic Kidney Disease	18
A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain?	18
Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort St	18
Ensifentrine Plus a Long-Acting Muscarinic Antagonist in COPD: A Trifunctional Dual Bronchodilation Perspective	18
Iptacopan: First Approval	18
Sipavibart: First Approval	18
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy	17
Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease	17
Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies	17
Vamorolone: First Approval	17
Sulbactam/Durlobactam: First Approval	17
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections	17
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?	17
Correction: Senaparib: First Approval	17
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors	17
Dimdazenil: First Approval	17
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy	16
Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials	16
Drugs in Development to Treat IgA Nephropathy	16
Mirvetuximab Soravtansine: First Approval	16
Linzagolix: First Approval	16
Fitusiran: First Approval	16
Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?	16
Vimseltinib: First Approval	16
Tunlametinib: First Approval	16
Drug-Induced Pigmentation: A Review	16
Authors’ Reply to Colak et al.: “Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing”	16
Chinese Herbal Medicines for Coronary Heart Disease: Clinical Evidence, Pharmacological Mechanisms, and the Interaction with Gut Microbiota	16
Tirzepatide: First Approval	16
Motixafortide: First Approval	16
Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians	15
Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis	15
Current and Emerging Therapies for Lysosomal Storage Disorders	15
Results from Expanded Access Programs: A Review of Academic Literature	15
Tegileridine: First Approval	15
Clesrovimab: First Approval	15
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions	15
Nemolizumab: First Approval	15
Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis	15
Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review	14
Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	14
Weight Loss Versus Glycemic Control as the Primary Treatment Target in Newly Diagnosed Type 2 Diabetes: Why Choose When You Can Have Both?	14
Pirtobrutinib: First Approval	14
Correction to: Daridorexant: First Approval	14
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy	14